EHA 2022 | Phase I/II study of milademetan plus low-dose cytarabine with or without venetoclax in R/R AML
Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, shares the results of a Phase I/II study assessing milademetan in combination with low-dose cytarabine with or without venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with wild-type TP53 (NCT03634228). Whilst the study reported a small number of dose-limiting toxicities, it did not report good response rates across the different dose levels that were tested. The study further evaluated the impact of milademetan on the risk of developing abnormal TP53 expression, and is currently exploring the markers of responses to this treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
